Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Financing Activities history runs 12 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 751.4% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $20.7 million, a 94.13% decrease from a year earlier, with the FY2025 full-year figure at $13.7 million, down 96.13% from the prior year.
• Cash from Financing Activities improved to $7.9 million in Q1 2026 per SNDX's latest filing, from $5.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $347.4 million in Q4 2024 and bottomed at -$13.5 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is $2.5 million (2023), against an average of $47.7 million.
• Across the five-year window, Cash from Financing Activities sank 893.26% in 2022 and soared 751.4% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $163.5 million in 2022, then soared by 58.09% to $258.5 million in 2023, then jumped by 34.41% to $347.4 million in 2024, then tumbled by 98.3% to $5.9 million in 2025, then surged by 33.82% to $7.9 million in 2026.
• Per Business Quant, the three latest SNDX Cash from Financing Activities figures stand at $7.9 million (Q1 2026), $5.9 million (Q4 2025), and $6.3 million (Q3 2025).